Assembly Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 65
- Market Cap
- -
- Website
- http://www.assemblybio.com
- Introduction
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 78
- Registration Number
- NCT06740474
- Locations
- 🇳🇿
New Zealand Clinical Research, Auckland, New Zealand
A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- Drug: ABI-1179 Placebo
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 146
- Registration Number
- NCT06698575
- Locations
- 🇦🇺
Momentum Sunshine, Melbourne, Au, Australia
🇦🇺East Sydney Doctors, Darlinghurst, Australia
🇦🇺Royal Melbourne Hospital, Parkville, Australia
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital Herpes
- Conditions
- Recurrent Genital Herpes Simplex Type 2
- Interventions
- Drug: ABI-5366 Placebo
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 146
- Registration Number
- NCT06385327
- Locations
- 🇦🇺
East Sydney Doctors, Darlinghurst, New South Wales, Australia
🇦🇺Taylor Square Private Clinic, Surry Hills, New South Wales, Australia
🇦🇺Momentum Sunshine, Melbourne, Victoria, Australia
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 20
- Registration Number
- NCT06384131
- Locations
- 🇲🇩
ARENSIA Exploratory Medicine Chisinau, Chisinau, Moldova, Republic of
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subjects
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: ABI-4334 TabletDrug: ABI-4334 Placebo
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 54
- Registration Number
- NCT05569941
- Locations
- 🇳🇿
New Zealand Clinical Research, Grafton, Auckland, New Zealand
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT05414981
- Locations
- 🇧🇬
Diagnostic Consultative Center Aleksandrovska, Sofia, Sofia City, Bulgaria
🇧🇬Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria
🇧🇬Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia, Sofia, Bulgaria
A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 65
- Registration Number
- NCT04820686
- Locations
- 🇦🇺
Saint Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
🇦🇺Saint George Hospital - Australia, Kogarah, New South Wales, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 54
- Registration Number
- NCT04781647
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Nanfang Hospital, First Military Medical University, Guangzhou, Guangdong, China
A Study to Evaluate the Mass Balance Absorption and AME of VBR
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Vebicorvir (VBR)
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 6
- Registration Number
- NCT04637139
- Locations
- 🇺🇸
Pharmaron CPC, Baltimore, Maryland, United States
A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Assembly Biosciences
- Target Recruit Count
- 2
- Registration Number
- NCT04454567
- Locations
- 🇺🇸
Asia Pacific Liver Center, Los Angeles, California, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸Research and Education, San Diego, California, United States